UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1023) 1023
science & technology (832) 832
life sciences & biomedicine (820) 820
azetidines - therapeutic use (623) 623
male (604) 604
ezetimibe (573) 573
female (532) 532
azetidines - adverse effects (453) 453
middle aged (437) 437
azetidines - administration & dosage (373) 373
anticholesteremic agents - therapeutic use (331) 331
aged (322) 322
drug therapy, combination (296) 296
treatment outcome (295) 295
adult (284) 284
biological and medical sciences (277) 277
medical sciences (274) 274
pharmacology & pharmacy (245) 245
hypercholesterolemia - drug therapy (231) 231
cholesterol, ldl - blood (227) 227
azetidines - pharmacology (226) 226
anticholesteremic agents - adverse effects (220) 220
cardiovascular system & cardiology (218) 218
abridged index medicus (193) 193
cholesterol (187) 187
anticholesteremic agents - administration & dosage (184) 184
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (175) 175
animals (174) 174
double-blind method (171) 171
cardiac & cardiovascular systems (165) 165
drug therapy (147) 147
general & internal medicine (140) 140
medicine, general & internal (140) 140
simvastatin - therapeutic use (139) 139
statins (139) 139
benzylamines (138) 138
dose-response relationship, drug (128) 128
anticoagulants - therapeutic use (118) 118
pharmacology. drug treatments (118) 118
risk factors (117) 117
azetidines - pharmacokinetics (115) 115
administration, oral (113) 113
hypercholesterolemia (113) 113
simvastatin (107) 107
anticoagulants - adverse effects (104) 104
lipids (101) 101
simvastatin - adverse effects (101) 101
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (99) 99
randomized controlled trials as topic (98) 98
drug combinations (95) 95
simvastatin - administration & dosage (95) 95
care and treatment (92) 92
hypercholesterolemia - blood (92) 92
cardiovascular (91) 91
clinical trials (91) 91
aged, 80 and over (89) 89
low density lipoproteins (89) 89
thrombin - antagonists & inhibitors (85) 85
cardiovascular disease (84) 84
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (84) 84
research (84) 84
cardiology. vascular system (82) 82
medicine & public health (81) 81
peripheral vascular disease (81) 81
ximelagatran (80) 80
clinical trials as topic (79) 79
atorvastatin calcium (78) 78
adolescent (76) 76
sulfonamides - therapeutic use (74) 74
anticholesteremic agents - pharmacology (72) 72
cholesterol - blood (69) 69
antilipemic agents (68) 68
time factors (67) 67
coronary heart disease (66) 66
dyslipidemias - drug therapy (65) 65
anticoagulants - administration & dosage (64) 64
cholesterol, ldl - drug effects (64) 64
drug interactions (64) 64
internal medicine (63) 63
triglycerides - blood (63) 63
young adult (63) 63
analysis (62) 62
metabolic diseases (61) 61
ezetimibe, simvastatin drug combination (60) 60
hyperlipidemias - drug therapy (60) 60
sulfonamides - administration & dosage (59) 59
cholesterol, hdl - blood (57) 57
pyrroles - therapeutic use (57) 57
cardiovascular diseases - prevention & control (56) 56
dosage and administration (56) 56
drug administration schedule (55) 55
pharmacology/toxicology (55) 55
pyrroles - administration & dosage (55) 55
anticoagulants (54) 54
cardiology (54) 54
atherosclerosis (53) 53
disorders of blood lipids. hyperlipoproteinemia (53) 53
lipids - blood (53) 53
sulfonamides - adverse effects (53) 53
heptanoic acids - administration & dosage (52) 52
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1063) 1063
German (22) 22
French (7) 7
Spanish (7) 7
Japanese (6) 6
Russian (5) 5
Hungarian (4) 4
Danish (3) 3
Polish (3) 3
Italian (2) 2
Portuguese (2) 2
Czech (1) 1
Lithuanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Clinical orthopaedics and related research, ISSN 0009-921X, 3/2008, Volume 466, Issue 3, pp. 714 - 721
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 191 - 200
Life Sciences & Biomedicine | Dermatology | Science & Technology | Humans | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thalidomide - analogs & derivatives | Isonicotinic Acids - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Pyrroles - administration & dosage | Adenosine - adverse effects | Adamantane - therapeutic use | Pyrroles - adverse effects | Adamantane - administration & dosage | Receptors, Lysosphingolipid - metabolism | Adamantane - analogs & derivatives | Isonicotinic Acids - adverse effects | Thalidomide - adverse effects | Biological Therapy | Isonicotinic Acids - therapeutic use | Piperidines - administration & dosage | Psoriasis - drug therapy | Adenosine A3 Receptor Antagonists - therapeutic use | Administration, Oral | Azetidines - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phosphodiesterase 4 Inhibitors - therapeutic use | Adenosine A3 Receptor Antagonists - adverse effects | Thalidomide - administration & dosage | Adenosine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Azetidines - therapeutic use | Adenosine - analogs & derivatives | Thalidomide - therapeutic use | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Thiazoles - administration & dosage | Thiazoles - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Phosphodiesterase 4 Inhibitors - administration & dosage | Adenosine - therapeutic use | Arthritis, Psoriatic - drug therapy | Pyrroles - therapeutic use | Adamantane - adverse effects | Adenosine A3 Receptor Antagonists - administration & dosage | Pyrimidines - administration & dosage | Clinical Trials as Topic | Niacinamide - administration & dosage | Biological Factors - therapeutic use | Janus Kinases - antagonists & inhibitors | Azetidines - administration & dosage | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
Journal Article
Pharmacotherapy, ISSN 0277-0008, 05/2020, Volume 40, Issue 5, pp. 416 - 437
dialysis | renal | antivirals | cytochrome P450 | infectious disease | liver | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pandemics | Alanine - adverse effects | Adrenal Cortex Hormones | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Thiazoles - administration & dosage | Hydroxychloroquine - adverse effects | Thiazoles - adverse effects | Alanine - analogs & derivatives | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ritonavir - adverse effects | Ribavirin - administration & dosage | Betacoronavirus | Antibodies, Monoclonal, Humanized - adverse effects | Ritonavir - administration & dosage | Immunomodulation | Azetidines - adverse effects | Chloroquine - adverse effects | Antiviral Agents - administration & dosage | Adenosine Monophosphate - adverse effects | Hydroxychloroquine - administration & dosage | Nelfinavir - adverse effects | Interferon-alpha - administration & dosage | Azetidines - administration & dosage | Ribavirin - adverse effects | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Coronavirus Infections - therapy | Immunization, Passive | Lopinavir - administration & dosage | Sulfonamides - adverse effects | Chloroquine - administration & dosage | Interferon-alpha - adverse effects | Nelfinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Sulfonamides - administration & dosage | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Antiviral agents | Therapeutic applications | Clinical trials | Coronaviruses | Drug therapy | Patients | Index Medicus | Reviews of Therapeutics | Review of Therapeutics
Journal Article
Journal of human genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Flucloxacillin | Risk groups | DQA1 protein | Allopurinol | Hypersensitivity | Liver | Drug development | Carbamazepine | Genetic screening | Ticlopidine | Quality of life | Side effects | Genetic markers | Abacavir | Histocompatibility antigen HLA | Pharmacogenomics | Index Medicus
Journal Article